vimarsana.com

Latest Breaking News On - Daobin zhou - Page 1 : vimarsana.com

InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Waldenström s Macroglobulinemia in China

/PRNewswire/ InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the Center for Drug Evaluation (CDE) of the China.

Hong kongNew jerseyUnited statesJasmine cuiDaobin zhouChunhua luPrnewswire innocare pharmaChina national medical products administrationNational reimbursement drugDrug administrationCare pharmaDrug evaluationNew drug applicationIndependent review committeeProfessor daobin zhouHematology department

InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Waldenström s Macroglobulinemia in China

/PRNewswire/ InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the Center for Drug Evaluation (CDE) of the China.

Hong kongNew jerseyUnited statesJasmine cuiDaobin zhouChunhua luPrnewswire innocare pharmaChina national medical products administrationNational reimbursement drugDrug administrationCare pharmaDrug evaluationNew drug applicationIndependent review committeeProfessor daobin zhouHematology department

Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH

/PRNewswire/ InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that leading PIs presented latest data of BTK inhibitor orelabrutinib.

United statesHong kongNew jerseyWei xuDaobin zhouOrelabrutinib monotherapyJianyong liMing houWaldenstrom macroglobulinemiaInnocare pharmaChunhua luAmerican society of hematologyChina national medical products administrationDrug administrationAmerican societyAnnual meeting

Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesHong kongNew jerseyWei xuDaobin zhouOrelabrutinib monotherapyPrnewswire innocare pharmaJianyong liMing houWaldenstrom macroglobulinemiaChunhua luAmerican society of hematologyChina national medical products administrationDrug administrationCare pharmaAmerican society

Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH

/PRNewswire/ InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that leading PIs presented latest data of BTK inhibitor orelabrutinib.

United statesHong kongNew jerseyWei xuDaobin zhouOrelabrutinib monotherapyJianyong liMing houWaldenstrom macroglobulinemiaInnocare pharmaChunhua luAmerican society of hematologyChina national medical products administrationDrug administrationAmerican societyAnnual meeting

vimarsana © 2020. All Rights Reserved.